The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

The CDMO will be cutting 350 jobs at its Baltimore gene therapy site after a major client’s demand shift, less than a year after Novo Holdings’ $16.5 billion acquisition.

Doustdar, a longtime company insider, took up the chief executive role on Aug. 7, a week after Novo Nordisk cut its outlook for the second time this year blaming competition from copycat versions of ...

By May of 2025, Novo's now-former chief executive, Lars Fruergaard Jørgensen, announced that he would be stepping down, ...